CD4 and COVID-19: Unequivocal data is provided that seroconversion induced by natural COVID-19 exposure does not negate significant expansion of polyfunctional SARS-CoV-2-specific CD4 + T-cells correlating with increased neutralising antibody titres following vaccination with two doses of either COVISHIELDTM or COVAXIN®.